Added Stakeholders, Added Value(s) to the Cognitive Enhancement Debate: Are Academic Discourse and Professional Policies Sidestepping Values of Stakeholders?

AJOB Primary Research

Volumn 3, Issue 1, 2012, Pages 33-47

  Forlini, Cynthia ^a   Racine, Eric ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

cognitive enhancement; focus groups; neuroethics; pragmatism; professional guidelines; stakeholder perspectives

Indexed keywords

EID: 84857196361     PISSN: 21507716     EISSN: 21507724     Source Type: Journal    
DOI: 10.1080/21507716.2011.645116     Document Type: Article

References (56)

1. Arria, A. M. and Wish, E. D. 2006. Nonmedical use of prescription stimulants among students. Pediatric Annals, 35(8): 565-571.
2. Babcock, Q. and Byrne, T. 2000. Student perceptions of methylphenidate abuse at a public liberal arts college. Journal of American College Health, 49(3): 143-145.
3. Banjo, O. C., Nadler, R. and Reiner, P. B. 2010. Physician attitudes towards pharmacological cognitive enhancement: Safety concerns are paramount. PLoS One, 5(12): e14322
4. Barrett, S. P., Darredeau, C., Bordy, L. E. and Pihl, R. O. 2005. Characteristics of methylphenidate misuse in a university student sample. Canadian Journal of Psychiatry, 50(8): 457-461.
5. Bergstrom, L. S. and Lynoe, N. 2008. Enhancing concentration, mood and memory in healthy individuals: An empirical study of attitudes among general practitioners and the general population. Scandinavian Journal of Public Health, 36(5): 532-537.
6. Bolt, I. and Schermer, M. 2009. Psychopharmacological enhancers: Enhancing identity?. Neuroethics, 2(2): 103-111.
7. British Medical Association. 2007. Boosting your brainpower: Ethical aspects of cognitive enhancement, 1-42. London: British Medical Association.
8. Bublitz, J. C. and Merkel, R. 2009. Autonomy and authenticity of enhanced personality traits. Bioethics, 23(6): 360-374.
9. Bush, S. S. 2006. Neurocognitive enhancement: Ethical considerations for an emerging subspecialty. Applied Neuropsychology, 13(2): 125-136.
10. Callahan, D. 2005. Bioethics and the culture wars. Cambridge Quarterly of Healthcare Ethics, 14(4): 424-431.
11. Canadian Pharmacists Association. 2008. "Ritalin". In e-Compendium of Pharmaceuticals and Specialties, 39th ed, Toronto: Canadian Pharmacists Association. Available at: www.e-therapeutics.ca
12. Chatterjee, A. 2004. Cosmetic neurology: The controversy over enhancing movement, mentation, and mood. Neurology, 63(6): 968-974.
13. Commission de l'éthique de la science de la technologie. 2009. Position statement on psychotropic drugs and expanded uses: An ethical perspective Québec, Canada
14. Dewey, J. 1922. Human nature and conduct: An introduction to social psychology New York, Holt
15. Farah, M. J., Illes, J., Cook-Deegan, R., Gardner, H., Kandel, E., King, P., Parens, E., Sahakian, B. and Wolpe, P. R. 2004. Neurocognitive enhancement: What can we do and what should we do?. Nature Reviews Neuroscience, 5(5): 421-425.
16. Farah, M. J. and Wolpe, P. R. 2004. Monitoring and manipulating brain function: New neuroscience technologies and their ethical implications. Hastings Center Report, 34(3): 35-45.
17. Forlini, C. and Racine, E. 2009a. Autonomy and coercion in academic "cognitive enhancement" using methylphenidate: Perspectives of a pragmatic study of key stakeholders. Neuroethics, 2(3): 163-177.
18. Forlini, C. and Racine, E. 2009b. Disagreements with implications: Diverging discourses on the ethics of non-medical use of methylphenidate for performance enhancement. BMC Medical Ethics, 10: 9
19. Forlini, C. and Racine, E. 2011. Considering the causes and implications of ambivalence in using medicine for enhancement. American Journal of Bioethics, 11(1): 15-17.
20. Forlini, C. and Racine, E. 2011, February. Does the cognitive enhancement debate call for a renewal of the deliberative role of bioethics?, Mainz, Germany: Cognitive Enhancement Conference for Young Scholars.
21. Forlini, C. and Racine, E. In press. Stakeholder perspectives and reactions to "academic" cognitive enhancement: Unsuspected meaning of ambivalence and analogies. Public Understanding of Science, First published online December 5, 2010 doi:10.1177/0963662510385062
22. Franke, A. G., Bonertz, C., Christmann, M., Huss, M., Fellgiebel, A., Hildt, E. and Lieb, K. 2011. Non-medical use of prescription stimulants and illicit use of stimulants for cognitive enhancement in pupils and students in Germany. Pharmacopsychiatry, 44(2): 60-66.
23. Greely, H., Sahakian, B., Harris, J., Kessler, R. C., Gazzaniga, M., Campbell, P. and Farah, M. J. 2008. Towards responsible use of cognitive-enhancing drugs by the healthy. Nature, 456(7224): 702-705.
24. Hall, W. 2004. Feeling 'better than well.'. EMBO Reports, 5(12): 1105-1109.
25. Hall, W. D. and Lucke, J. C. 2010. The enhancement use of neuropharmaceuticals: More scepticism and caution needed. Addiction, 105: 2041-2043.
26. Hotze, T., Shaw, K., Anderson, E. and Wynia, M. 2011. "Doctor, would you prescribe a pill to help me...?" A national survey of physicians on using medicine for human enhancement. American Journal of Bioethics, 11(1): 3-13.
27. Larriviere, D. and Williams, M. A. 2010. Neuroenhancement: Wisdom of the masses or "false phronesis"?. Clinical Pharmacology & Therapeutics, 88(4): 459-461.
28. Larriviere, D., Williams, M. A., Rizzo, M. and Bonnie, R. J. 2009. Responding to requests from adult patients for neuroenhancements. Guidance of the Ethics, Law and Humanities Committee. Neurology, 73(17): 1406-1412.
29. Laurance, J. 2003. Abuse hits students looking for an exam kick. The Independent, August 26, 5
30. Levy, N. 2007. Neuroethics: Challenges for the 21st century, Cambridge: Cambridge University Press.
31. Lucke, J. C., Bell, S., Partridge, B. and Hall, W. D. 2010. Weak evidence for large claims contribute to the phantom debate. BioSocieties, 5(4): 482-483.
32. McKenna, S. A. 2011. Reproducing hegemony: The culture of enhancement and discourses on amphetamines in popular fiction. Culture, Medicine and Psychiatry, 35(1): 9-97.
33. Mehlman, M. J. 2004. Cognition-enhancing drugs. Milbank Quarterly, 82(3): 483-506.
34. Morency, K. 2006. More students abusing Ritalin as study aid: 'It really not hard to get hold of' abuse rate among students at 5% to 10% and is rising, Concordia officials say. Montreal Gazette, January 8, A3
35. Outram, S. M. 2010. The use of methylphenidate among students: The future of enhancement?. Journal of Medical Ethics, 36(4): 198-202.
36. Outram, S. M. and Racine, E. 2011. Developing public health approaches to cognitive enhancement: An analysis of current reports. Public Health Ethics, 4(1): 93-105.
37. Parens, E. 2005. Authenticity and ambivalence: Toward understanding the enhancement debate. Hastings Center Report, 35(3): 34-41.
38. Parens, E. and Johnston, J. 2007. Does it make sense to speak of neuroethics? Three problems with keying ethics to hot new science and technology. EMBO Reports, 8(spec. no.): S61-S64
39. President's Council on Bioethics. 2003. Beyond therapy, Washington, DC: President's Council on Bioethics/Harper Collins.
40. Rabiner, D. L., Anastopoulos, A. D., Costello, E. J., Hoyle, R. H., McCabe, S. E. and Swartzwelder, H. S. 2008. Motives and perceived consequences of nonmedical ADHD medication use by college students: Are students treating themselves for attention problems?. Journal of Attention Disorders, 13(3): 259-270.
41. Racine, E. 2010. Pragmatic neuroethics: Improving treatment and understanding of the mind-brain, Cambridge, MA: MIT Press.
42. Racine, E. and Forlini, C. 2010. Correspondence: Responding to requests from adult patients for neuroenhancements: Guidance of the ethics, law and humanities committee. Neurology, 74(19): 1555-1556.
43. Racine, E. and Forlini, C. 2010. Cognitive enhancement, lifestyle choice or misuse of prescription drugs? Ethical blindspots in current debates. Neuroethics, 3(1): 1-14.
44. Repantis, D., Laisney, O. and Heuser, I. 2010a. Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: A systematic review. Pharmacological Research, 61(6): 473-481.
45. Repantis, D., Schlattmann, P., Lainsey, O. and Heuser, I. 2008. Antidepressants for neuroenhancement in healthy individuals: A systematic review. Poiesis & Praxis, 6(3-4): 139-174.
46. Repantis, D., Schlattmann, P., Lainsey, O. and Heuser, I. 2010b. Modafinil and methylphenidate for neuroenhancement in healthy individuals: A systematic review. Pharmacological Research, 62(3): 187-206.
47. Riis, J., Simmons, J. P. and Goodwin, G. P. 2008. Preferences for enhancement pharmaceuticals: The reluctance to enhance fundamental traits. Journal of Consumer Research, 35: 495-508.
48. Ross, S. 2006. Students turn to smart drugs for exam help. The Scotsman, June 2, 7
49. Sabini, J. and Monterosso, J. 2005. Judgments of the fairness of using performance enhancing drugs. Ethics & Behavior, 15(1): 81-94.
50. Sandel, M. J. 2004. The case against perfection: What's wrong with designer children, bionic athletes, and genetic engineering. Atlantic Monthly, 292(3): 50-62.
51. Teter, C. J., McCabe, S. E., Boyd, C. J. and Guthrie, S. K. 2003. Illicit methylphenidate use in an undergraduate student sample: Prevalence and risk factors. Pharmacotherapy, 23(5): 609-617.
52. Teter, C. J., McCabe, S. E., Cranford, J. A., Boyd, C. J. and Guthrie, S. K. 2005. Prevalence and motives for illicit use of prescription stimulants in an undergraduate student sample. Journal of American College Health, 53(6): 253-262.
53. Teter, C. J., McCabe, S. E., LaGrange, K., Cranford, J. A. and Boyd, C. J. 2006. Illicit use of specific prescription stimulants among college students: Prevalence, motives, and routes of administration. Pharmacotherapy, 26(10): 1501-1510.
54. White, B. P., Becker-Blease, K. A. and Grace-Bishop, K. 2006. Stimulant medication use, misuse, and abuse in an undergraduate and graduate student sample. Journal of American College Health, 54(5): 261-268.
55. Wilens, T. E., Adler, L. A.Adams, J. 2008. Misuse and diversion of stimulants prescribes for ADHD: A systematic review of the literature. Journal of the American Academy of Child and Adolescent Psychiatry, 47(1): 21-31.
56. Zernike, K. 2005. The difference between steriods and Ritalin is.... The New York Times, March 20, 3